



Stockholm, Sweden

Press release October 31, 2018

Number of shares and votes in Oncopeptides

Stockholm – October 31, 2018 – Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company's incentive programs

Through the exercise of warrants under the company's incentive programs, the number of outstanding shares and votes will increase by 21,600 from 44,048,721 to 44,070,321. The share capital will increase by approximately SEK 2,400 from SEK 4,894,302 to SEK 4,896,702.

For further information, please contact:

Jakob Lindberg, CEO of Oncopeptides

Telephone: +46 8 615 20 40

Email: jakob.lindberg@oncopeptides.com

Rein Piir, Head of Investor Relations at Oncopeptides

Cell phone: +46 70 853 72 92

Email: rein.piir@oncopeptides.com

This is information that Oncopeptides AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on October 31, 2018 at 13.00 (CET).

About Oncopeptides

Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen (Ygalo[®]), an alkylating peptide, belonging to a new class of drugs (Peptidase Enhanced Compounds - PEnCs). Melflufen (Ygalo[®]) is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with melflufen (Ygalo[®]) compared with established alternative drugs for patients with late-stage multiple myeloma. Melflufen (Ygalo[®]) will potentially provide physicians with a new treatment option for patients suffering from this serious disease.

More information is available on www.oncopeptides.com.